

World Journal of *Gastroenterology*

World J Gastroenterol 2022 November 14; 28(42): 6002-6077



REVIEW

- 6002** Role of radiomics in the diagnosis and treatment of gastrointestinal cancer
Mao Q, Zhou MT, Zhao ZP, Liu N, Yang L, Zhang XM
- 6017** COVID-19 associated liver injury: A general review with special consideration of pregnancy and obstetric outcomes
Cooper KM, Colletta A, Asirwatham AM, Moore Simas TA, Devuni D

MINIREVIEWS

- 6034** Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy
Li SQ, Yang Y, Ye LS

ORIGINAL ARTICLE

Retrospective Cohort Study

- 6045** Clinical value of predictive models based on liver stiffness measurement in predicting liver reserve function of compensated chronic liver disease
Lai RM, Wang MM, Lin XY, Zheng Q, Chen J

Retrospective Study

- 6056** Novel management indications for conservative treatment of chylous ascites after gastric cancer surgery
Kong PF, Xu YH, Lai ZH, Ma MZ, Duan YT, Sun B, Xu DZ

Clinical Trials Study

- 6068** Computed tomography perfusion in liver and spleen for hepatitis B virus-related portal hypertension: A correlation study with hepatic venous pressure gradient
Wang L, Zhang Y, Wu YF, Yue ZD, Fan ZH, Zhang CY, Liu FQ, Dong J

ABOUT COVER

Editorial Board of *World Journal of Gastroenterology*, Andrada Seicean, MD, PhD, Professor, Regional Institute of Gastroenterology and Hepatology, University of Medicine and Pharmacy, 19-21 Croitorilor Street, Cluj-Napoca 400192, Romania. andrada.seicean@umfcluj.ro

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports, Index Medicus, MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJG as 5.374; IF without journal self cites: 5.187; 5-year IF: 5.715; Journal Citation Indicator: 0.84; Ranking: 31 among 93 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG's CiteScore for 2021 is 8.1 and Scopus CiteScore rank 2021: Gastroenterology is 18/149.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yu; Production Department Director: Xu Guo; Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

November 14, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Retrospective Study

Novel management indications for conservative treatment of chylous ascites after gastric cancer surgery

Peng-Fei Kong, Yong-Hu Xu, Zhi-Hua Lai, Ming-Zhe Ma, Yan-Tao Duan, Bo Sun, Da-Zhi Xu

Specialty type: Food Science and technology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B, B
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Aoki H, Japan; Ilhan E, Turkey

Received: June 27, 2022

Peer-review started: June 27, 2022

First decision: August 1, 2022

Revised: August 15, 2022

Accepted: October 26, 2022

Article in press: October 26, 2022

Published online: November 14, 2022



Peng-Fei Kong, Yong-Hu Xu, Ming-Zhe Ma, Yan-Tao Duan, Bo Sun, Da-Zhi Xu, Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China

Zhi-Hua Lai, Department of the General Surgery, Suzhou Industrial Park Xinghai Hospital, Suzhou 215124, Jiangsu Province, China

Corresponding author: Da-Zhi Xu, MD, PhD, Chief Doctor, Professor, Surgeon, Department of Gastric Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong'an Road, Shanghai 200032, China. xudzh@shca.org.cn

Abstract

BACKGROUND

Chylous ascites (CA) presents a challenge as a relatively common postoperative complication in gastric cancer (GC). Primary conservative therapy involved total parenteral nutrition, continuous low-pressure drainage, somatostatin, and a low-fat diet. Drainage tube (DT) clamping has been presented as a potential alternative conservative treatment for GC patients with CA.

AIM

To propose novel conservative treatment strategies for CA following GC surgery.

METHODS

The data of patients with CA after GC surgery performed at the Fudan University Shanghai Cancer Center between 2006 and 2021 were evaluated retrospectively.

RESULTS

53 patients underwent surgery for GC and exhibited postoperative CA during the study period. Postoperative hospitalization and time of DT removal showed a significant positive association ($R^2 = 0.979$, $P < 0.001$). We further observed that delayed DT removal significantly extended the total and postoperative hospitalization, antibiotic usage duration, and hospitalization cost (postoperative hospitalization: 25.8 d vs 15.5 d, $P < 0.001$; total hospitalization: 33.2 d vs 24.7 d, $P < 0.01$; antibiotic usage duration: 10.8 d vs 6.2 d, $P < 0.01$; hospitalization cost: $¥9.2 \times 10^4$ vs $¥6.5 \times 10^4$, $P < 0.01$). Multivariate analysis demonstrated that postoperative infection and antibiotic usage were independent factors for delayed DT removal. Furthermore, DT removal times were shorter in seven patients who underwent DT clamping (clamped DT vs normal group, 11.8 d vs 13.6 d, $P = 0.047$; clamped DT vs delayed group, 13.6 d vs 27.4 d, $P < 0.001$). In addition, our results indicated

that removal of the DT may be possible after three consecutive days of drainage volumes less than 300 mL in GC patients with CA.

CONCLUSION

Infection and antibiotic usage were vital independent factors that influenced delayed DT removal in patients with CA. Appropriate standards for DT removal can significantly reduce the duration of hospitalization. Furthermore, DT clamping might be a recommended option for conservative treatment of postoperative CA.

Key Words: Gastric cancer; Chylous ascites; Conservative treatment; Drainage tube

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Chylous ascites (CA) is one of uncommon postoperative complication in the patients received gastric cancer (GC) surgery. Previously, the primary treatment for CA was conservative therapy, which mainly involved total parenteral nutrition, continuous low-pressure drainage, somatostatin, and a low-fat diet. Therefore, we retrospectively analyzed the patients with CA after GC surgery in our center, aiming to explore the vital factors that influence CA treatment and recommend novel conservative treatment strategies for postoperative CA in GC.

Citation: Kong PF, Xu YH, Lai ZH, Ma MZ, Duan YT, Sun B, Xu DZ. Novel management indications for conservative treatment of chylous ascites after gastric cancer surgery. *World J Gastroenterol* 2022; 28(42): 6056-6067

URL: <https://www.wjgnet.com/1007-9327/full/v28/i42/6056.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v28.i42.6056>

INTRODUCTION

Chylous ascites (CA) was first reported by Morton in 1691 and is defined as the leakage of milk-like fluid that contains high level of triglyceride (TG)[1,2]. Gastric cancer (GC) is one of the most common malignant tumors worldwide, and a standardized protocol for radical surgical resection has been widely accepted as a safe and effective treatment[3,4]. CA generally occurs following abdominal surgery, the incidence of postoperative CA ranges from 2.06% to 11.80% in GC patients[5-7], as a result of disturbance of the cisterna chyli or its major tributaries[8,9]. The increased incidence of CA is considered to be likely due to the increased number of cancer patients undergoing more aggressive surgical interventions in addition to laparoscopic surgery[10]. CA presents a challenge as a relatively common postoperative complication and impacts subsequent adjuvant treatments in GC. In addition, massive and prolonged CA may lead to infection, malnutrition and immunodeficiency[11].

To date, treatment options for CA have included dietary measures, use of pharmacological agents and surgical or percutaneous interventions. A high-protein and low-fat diet with medium-chain triglycerides is often recommended for patients with CA[12]. Patients who do not respond to dietary restriction should receive total parenteral nutrition (TPN), which bypasses the bowel and may thus reduce lymph flow[13]. Continuous low-pressure drainage and somatostatin also represent effective conservative treatment for postoperative CA[6,14]. CA can be cured by lymphangiography and adjunctive embolization techniques that include direct percutaneous injection of glue into the leakage site or into the surrounding lymphoid tissue[15]. Furthermore, the use of surgical measures to successfully treat CA has been reported in patients with cirrhosis and CA that is resistant to conservative therapy[1].

In this study, we retrospectively analyzed 53 patients with CA after GC surgery, aiming to explore the vital factors that influence CA treatment and recommend novel conservative treatment strategies for postoperative CA in GC.

MATERIALS AND METHODS

Patients

We retrospectively reviewed all patients with CA who had undergone surgery for GC at our institution from 1 March 2006 to 31 May 2021. Three investigators performed a thorough review of all available data from the Fudan University Shanghai Cancer Center (FUSCC) medical record system, using RED

Cap electronic data capture tools. In this cohort, 53 patients were admitted for gastric resection and lymphadenectomy: 2 underwent palliative resection and 51 underwent radical gastric resection with curative intent. This study was approved by the FUSCC review board in accordance with Chinese bioethical regulations, and all enrolled patients signed informed consent forms.

Definitions

CA was defined as the presence of milky or creamy peritoneal fluid in the drainage tubes, at a volume of ≥ 200 mL/d and a TG levels ≥ 110 mg/dL[1,11]. Additionally, the chyle test was routinely performed if the milky peritoneal fluid was suspected to be CA[16]. Clinical and pathological data, including the age, gender, AJCC (American Joint Committee on Cancer) stage, surgical procedure, lymph node dissection, drainage tube (DT) removal, time of oral feeding, time to CA onset, drainage duration, and hospitalization duration were collected and analyzed. All patients with CA were managed conservatively; the conservative treatments included TPN, continuous low-pressure drainage, somatostatin, DT clamping, and a low-fat diet. The time to CA onset was defined as the interval between the surgical procedure and the appearance of CA. Delay DT removal was defined as a DT removal time > 16 d after surgery for all patients or patients discharge with DT. Additionally, white blood cell counts, body temperature measurement, and germiculture were performed to diagnose CA combined with infection. DT clamping is defined as physical closing of the abdominal DT, with a daily open drainage time of about 2 h.

Statistical analysis

Categorical variable analysis was performed using the χ^2 test or Fisher's exact test, and continuous variables were compared using Student's t test. We used univariate logistic regression models to evaluate the risk factors of delayed DT removal in GC patients with postoperative CA, and a Cox regression model was used to perform multivariable analysis to calculate relative risk. All values were categorized into groups according to medians. All results were considered clinically significant at a P value < 0.05 . Statistical analyses were performed using SPSS software version 19.0.

RESULTS

Clinical characteristics of gastric cancer patients with postoperative chylous ascites

Between 1 March 2006 and 31 May 2021, 16074 GC patients were hospitalized in our department and 7081 patients underwent gastrectomy and lymphadenectomy. Of these patients, 53 underwent surgical resection for GC and developed CA. The main characteristics and patient selection are shown in [Table 1](#) and [Figure 1](#). The patients had an average age of 61.0 ± 11.3 years, a high ratio of male and advanced stage of disease (Male *vs* female: 77.40% *vs* 22.60%, early stage *vs* advanced stage: 39.6% *vs* 60.4%), 51 underwent radical surgery, 43 underwent D2 lymph node dissection, and 13 were discharged with DT. The average oral feeding and CA onset times after surgery were 3.8 and 7.5 d, respectively. The average durations of DT drainage and postoperative hospitalization were 14.3 and 21.9 d, respectively.

Delayed drainage tube removal has an important influence on gastric cancer patients with postoperative chylous ascites

In our data, 40 patients (75%) had their DTs removed during the hospitalization period, and 13 patients (25%) were discharged with DT ([Figure 2A](#)). As shown in [Figure 2B](#) and [Supplementary Figure 1](#), both postoperative ($R^2 = 0.979$, $P < 0.001$) and total hospitalization time ($R^2 = 0.791$, $P < 0.001$) had a significant positive association with DT removal time. Moreover, the median postoperative DT removal time of the patients discharged with or without DT was 30 and 16 d, respectively ([Figure 2C](#) and [Supplementary Figure 2](#)). We defined the patients' DT removal time $>$ the median time (16 d) or the patients discharged with DT as delayed DT removal, and the patients were categorized into either the delayed DT removal or normal group ([Figure 2D](#)). Comparing the delayed and normal groups, delayed DT removal significantly extended the total and postoperative hospitalization times, duration of antibiotic usage, and hospitalization costs in the GC patients (postoperative hospitalization duration: 25.8 d *vs* 15.5 d, $P < 0.001$; total hospitalization duration: 33.2 d *vs* 24.7 d, $P < 0.01$; antibiotic usage: 10.8 d *vs* 6.2 d, $P < 0.01$; hospitalization cost: $\text{¥}9.2 \times 10^4$ *vs* $\text{¥}6.5 \times 10^4$, $P < 0.01$) ([Figure 2E](#)).

Characteristic differences between the normal and delayed drainage tube removal groups in gastric cancer patients with postoperative chylous ascites

We present the characteristic differences between the normal and delayed DT removal groups in [Figure 3](#), [Table 2](#) and [Supplementary Table 1](#). First, we evaluated the clinical characteristics and detected that there were no differences between the two groups regarding gender, age, tumor size or location, lymphadenectomy, and AJCC stage. Second, the treatment-related features were further explored. Of note, the patients in the normal group were more likely to undergo DT clamping than the delayed DT removal group (35.0% *vs* 0%, $P < 0.001$). In addition, compared with the patients in the delayed group, a

Table 1 Clinical characteristics of gastric cancer patients with postoperative chylous ascites

Characteristics	Cases
Age, yr	61.0 ± 11.3
Gender, <i>n</i> (%)	
Male	41 (77.4)
Female	12 (22.6)
Tumor location, <i>n</i> (%)	
Upper	18 (40.0)
Middle	11 (20.6)
Bottom	24 (45.3)
AJCC 8 th stage, <i>n</i> (%)	
I	21 (39.6)
II	11 (20.8)
III	18 (34.0)
IV	3 (5.7)
Type of surgery, <i>n</i> (%)	
Radical	51 (96.2)
Non-radical	2 (3.8)
LN dissection, <i>n</i> (%)	
D1	8 (15.1)
D2	43 (81.1)
D3	2 (3.8)
Discharged without DT, <i>n</i> (%)	
Yes	40 (75.5)
No	13 (24.5)
Postoperative time of oral feeding (d)	3.8 ± 1.0
Postoperative time of CA appearance (d)	7.5 ± 2.4
DT removal duration (d)	14.3 ± 12.6
Postoperative hospitalization duration (d)	21.9 ± 11.1

SD: Standard deviation; AJCC: American Joint Committee on Cancer; LN: Lymph node; DT: Drainage tube; CA: Chylous ascites.

shorter duration of low-fat diet were slightly shared in the normal group patients (40.0% *vs* 63.6%, $P = 0.082$). Third, we estimated the DT drainage variation between the two groups. Obviously, the delayed DT removal group generally had a longer duration of DT drainage than the normal group; however, the CA onset time and maximum drainage volumes were not significantly different between the two groups.

Infection and antibiotic usage were key independent factors influencing the delay of drainage tube removal

As shown in Table 3 and Figure 4, the univariate analysis revealed that early postoperative intake (RR: 2.22, 1.10–4.48, $P = 0.031$), postoperative infection (RR: 2.20, 1.21–4.61, $P = 0.003$), and antibiotic usage (RR: 0.45, 0.22–0.91, $P = 0.009$) were significantly associated with delayed DT removal in GC patients with CA. However, the baseline characteristics (age, gender, and AJCC stage), lymph node dissection, CA onset time, maximum drainage volume, postoperative albumin, postoperative hemoglobin, and DT clamping were not significantly associated with delayed DT removal (all $P > 0.05$). Furthermore, multivariate analysis demonstrated that postoperative infection (HR: 2.40, 1.63–4.14, $P = 0.007$) and antibiotic usage (HR: 0.86, 0.76–0.96, $P = 0.009$) were independent factors that influenced delayed DT removal in GC patients with postoperative CA.

Table 2 Clinical characteristics differences between the normal and delayed drainage tube removal groups

Subgroup	No. of patients	
	Normal (<i>n</i> = 20)	Delayed DT removal (<i>n</i> = 33)
Clamp DT		
Yes	7	0
No	13	0
Preoperative HGB, g/L		
≤ 130	12	15
> 130	8	18
Preoperative ALB, g/L		
≤ 41	9	17
> 41	11	16
Maximum drainage, mL		
≤ 540	13	13
> 540	7	20
Postoperative intake ¹ , d		
≤ 3	10	17
> 3	10	16
CA onset time, d		
≤ 7	15	16
> 7	5	17
Antibiotic usage, d		
≤ 5	12	16
> 5	8	17
Postoperative infection		
Yes	8	12
No	12	21
AJCC stage		
Early	8	13
Advanced	12	20
LN dissection		
D1	6	2
D2+	14	31
Age, yr		
≤ 60	8	15
> 60	12	18
Gender		
Male	15	26
Female	5	7

¹Time of oral feeding after gastric surgery.

HGB: Hemoglobin; ALB: Albumin; AJCC: American Joint Committee on Cancer; LN: Lymph node; DT: Drainage tube; CA: Chylous ascites.

Table 3 Postoperative infection-related complications significantly affect gastric cancer patients with postoperative chylous ascites to remove abdominal drainage tubes in time

	Univariate analysis		Multivariate analysis	
	HR (95%CI)	P value	HR (95%CI)	P value
DT clamping	0.39 (0.11-1.72)	0.281	-	-
Postoperative HGB	1.49 (0.72-3.08)	0.283	-	-
Postoperative ALB	1.82 (0.88-3.76)	0.303	1.09 (0.98-1.21)	0.127
Maximum drainage	0.98 (0.47-2.05)	0.367	-	-
Postoperative intake time	2.22 (1.10-4.48)	0.031	1.86 (0.94-4.21)	0.234
CA onset time	0.81 (0.40-1.62)	0.486	-	-
Duration of antibiotic usage	0.45 (0.22-0.91)	0.009	0.86 (0.76-0.96)	0.009
Postoperative infection	2.20 (1.21-4.61)	0.003	2.40 (1.63-4.14)	0.007
AJCC Stage	0.95 (0.75-1.21)	0.676	-	-
LN dissection	0.87 (0.53-1.42)	0.595	-	-
Age	1.34 (0.66-2.70)	0.471	-	-
Gender	2.02 (0.85-4.78)	0.141	3.13 (0.85-11.1)	0.187

HR: Hazard ratio; CI: Confidence interval; HGB: Hemoglobin; ALB: Albumin; AJCC: American Joint Committee on Cancer; LN: Lymph node; DT: Drainage tube; CA: Chylous ascites.




Figure 1 Flowchart of study included patients. ¹Include the patients underwent neo-adjuvant, adjuvant, and palliative chemotherapy. ²Include the patients with anastomotic stenosis and fistula, except for the patients with anastomotic bleeding. ³The patients with all infection events except abdominal infection. GC: Gastric cancer; DT: Drainage tube; TG: Triglyceride.

Drainage tube clamping is a favorable method for the gastric cancer patients with postoperative chylous ascites

In Figure 5A, we describe comprehensive treatment for GC patients with postoperative CA; the therapies included DT clamping, somatostatin, antibiotic, TPN, low-fat diet, and continuous low-pressure drainage. DT clamping was performed for seven patients during the hospitalization period when postoperative CA occurred, and the clamped DT patients had a shorter DT removal time than the nor-




Figure 2 Delayed drainage tube removal has an important influence on gastric cancer patients with postoperative chylous ascites. ^b $P < 0.01$. ^c $P < 0.001$. A: The status of drainage tube (DT) after discharged in gastric cancer (GC) patients with postoperative chylous ascites (CA); B: Postoperative hospitalization have a significantly positive correlation with the time of removal DT in GC patients discharged without DT; C: Time of removal DT in GC patients with postoperative CA who discharged without DT; D: The definition of delayed DT removal in GC patients with postoperative CA; E: Delayed DT removal obviously increase medical resources consumption and economic burden in GC patients with postoperative CA. GC: Gastric cancer; CA: Chylous ascites; DT: Drainage tube; PHD: Postoperative hospitalization duration; THD: Total hospitalization duration; AU: time of antibiotic usage; HC: Hospitalization cost.

mal and delayed removal groups (clamped DT group *vs* normal group, 11.8 d *vs* 13.6 d, $P = 0.047$; clamped DT group *vs* delayed group, 13.6 d *vs* 27.4 d, $P < 0.001$) (Figure 5B and Supplementary Figure 3). Moreover, similar clinical characteristics and treatment strategies were present in the three sub-groups (Supplementary Table 2). Our result further indicated that DT clamping significantly decreased total and postoperative hospitalization time, duration of antibiotic usage, and hospitalization costs in the GC patients with CA (Supplementary Figure 4). In Figure 5C, we dynamically observed the variation in daily drainage volume before DT removal (day 1 to day 7). Compared with the delayed removal group, start from day 3 before remove DT, the normal group and the clamped-DT group had relatively high drainage volumes. Additionally, the results of the drainage variation analysis indicated that 3 consecutive days of drainage volume less than 300 mL may be a suitable remove DT threshold in the GC patients with postoperative CA. Among two patients underwent DT clamping, computed tomography imaging of the abdomen showed that, after about 1 wk of DT clamping, the fluid in the abdominal cavity was reduced (Figure 5D).

Novel conservative therapeutic strategies for gastric cancer patients with postoperative chylous ascites

As the results mentioned above, we subsequently summarized the experiences of the GC patients with postoperative CA treatment in our department (Figure 6). First, the CA patients were divided into two sub-groups according to their postoperative infection status. Second, in the patients with infection, based on traditional treatments, antibiotic therapy was a vital supplement. Third, in the patients without infection, DT clamping was a viable option. Finally, for patients with 3 consecutive days of drainage less than 300 mL, DT removal might be the appropriate management.

DISCUSSION

In this study, we retrospectively analyzed 53 cases of GC with postoperative CA at the FUSCC. Our results indicated that hospitalization duration was closely associated with DT removal time. Furthermore, postoperative infection and antibiotic usage were important independent factors that




Figure 3 Overview of characteristic differences between the normal and delayed drainage tube removal groups in gastric cancer patients with postoperative chylous ascites. GC: Gastric cancer; DT: Drainage tube; LN: Lymph node; CA: Chylous ascites.




Figure 4 Exploration of multiple factors influence drainage tube removal in gastric cancer patients with postoperative chylous ascites. GC: Gastric cancer; DT: Drainage tube; LN: Lymph node; CA: Chylous ascites.

influenced delayed DT removal in GC patients with postoperative CA. Our study also implied that DT clamping was an appropriate method of postoperative CA treatment for patients without postoperative infection. More importantly, appropriate and lenient indications for DT removal can significantly reduce the duration of hospitalization.




Figure 5 Drainage tube clamping is a favorable method for the gastric cancer patients with postoperative chylous ascites. A: Overview of overall treatment in the gastric cancer (GC) patients with postoperative chylous ascites; B: The drainage tube (DT) drainage variation of the GC patients underwent the treatment of DT clamping; C: The drainage of GC patients with postoperative chylous ascites in different groups before DT removal; D: Computed tomography scan indicate that the fluid in abdominal cavity was clearly reduced after the DT was clamped. THD: Total hospitalization duration; TPN: Total parenteral nutrition; CLD: Continuous low-pressure drainage; GC: Gastric cancer; DT: Drainage tube; CA: Chylous ascites; LN: Lymph node. ^a $P < 0.05$. ^c $P < 0.001$.




Figure 6 Novel conservative therapeutic strategies for gastric cancer patients with postoperative chylous ascites. TPN: Total parenteral nutrition; CLD: Continuous low-pressure drainage; GC: Gastric cancer; DT: Drainage tube; CA: Chylous ascites.

In most of the GC patients, postoperative CA cannot be discharged at a routine time and have a significant impact on subsequent adjuvant treatment[6,7]. Normally, patients are discharged within 7 d after undergoing GC surgery and most start adjuvant treatment within 30 d at our center. However, in the 53 patients with postoperative CA in our study, the average postoperative hospitalization duration was 21.9 d, and 8 patients' postoperative hospital stays were longer than 30 d. As previously reported, lymphadenectomy was a key influencing factor in GC patients with postoperative CA[5,9]. As shown in

Supplementary Table 3, the clinical characteristics of patients with CA tended to be consistent among those who underwent variety of lymphadenectomy, similar with previous studies that CA was found to be a rare complication even for gastric carcinoma patients undergoing D3 dissection[5,17].

Our results clearly indicated that hospitalization duration is mainly dependent on the time of DT removal in GC patients with CA. A multi-center prospective study recommended the criterion for DT removal be drainage flow between 500 and 1000 mL/d[6]. In fact, we previously performed relatively rigorous standards for DT removal in the patients with CA. Usually, while the volume of drainage less than 100 mL/d, the DT removal will be truly considered. Although all the patients' DTs were removed until the flow volume less than 300 mL/d, and the delayed removal group preferred to perform a significantly high criterion. Therefore, we have a sufficient reason to conclude that, after excluding the influence of postoperative infection, early DT removal is a better choice in GC patients with CA. Moreover, our study found that postoperative infection and antibiotic usage were vital independent factors that influenced delayed DT removal in patients with CA, and clearly clarified anti-infection were an effective supplemental therapy for conservative treatment of postoperative CA. Similarly, Lu *et al*[7] reported the patients with CA had a certain higher level of postoperative white blood cell counts than the other patients in GC.

Previously, the primary treatment for CA was conservative therapy, which mainly involved TPN, continuous low-pressure drainage, somatostatin, and a low-fat diet[18]. Recently, DT clamping has been presented as a potential alternative for patients with CA in other malignancies[19]. In this study, the DTs of 7 patients were clamped until the daily drainage was less than 500 mL/d (or ½ the maximum drainage). After DT clamping, the flow amount was significantly reduced, and the patients were successfully discharged without DT. For the reason of clamping DT facilitates DT removal, previous research has demonstrated absorption and lymphatic drainage increase along with the interstitial hydrostatic pressure[20]. Furthermore, DT clamping could help to evaluate the feasibility of DT removal by conveniently simulating the removal and conversion back to drainage[21]. Several studies have suggested DT clamping as an important alternative, and the detailed suggestion was daily drainage ranging from 1000 to 1500 mL[6,22]. However, a consensus on the threshold of drainage volume for DT clamping has not yet been reached. Therefore, determination of an appropriate criterion for DT removal and DT clamping is urgently needed for GC patients with postoperative CA.

There are certain limitations to our study. First, due to the retrospective study design, it was difficult to individually balance a variety of influencing factors; thus, various biases were unavoidable. Second, despite routine chyle test and TG were measured, the definition of CA is slightly less rigorous. In particular, CA with co-infection cannot fully rule-out the influence of pancreatic and anastomotic leakage, and other infection-related complications. In addition, small-volume CA (*i.e.*, daily drainage volume ranging from 30 to 200 mL) was not considered in this study.

CONCLUSION

In conclusion, postoperative infection and antibiotic usage were vital independent factors that influenced delayed DT removal in GC patients with CA. Appropriate and lenient standards for DT removal can significantly reduce the duration of hospitalization. Furthermore, DT clamping might be a recommend alternative for conservative treatment of postoperative CA.

ARTICLE HIGHLIGHTS

Research background

Chylous ascites (CA) is relatively common postoperative complication in patients undergoing received gastric cancer (GC) surgery that obviously prolongs hospitalization and has a major impacts on subsequent adjuvant treatments.

Research motivation

Drainage tube (DT) clamping has been presented as a potential alternative conservative treatment for GC patients with CA.

Research objectives

This study aimed to explore key factors influencing CA treatment and recommend novel conservative treatment strategies for postoperative CA in GC patients.

Research methods

Data from patients with CA after GC surgery performed at the Fudan University Shanghai Cancer Center between 2006 and 2021 were retrospectively evaluated. Patients were classified into two distinct

groups with respect to DT removal time. We further explored the differences in clinical-pathological features of the different DT removal groups.

Research results

Fifty-three patients underwent surgery for GC and experienced postoperative CA during the study period. Postoperative hospitalization and DT removal time showed a significant positive association ($R^2 = 0.979$, $P < 0.001$), while delayed DT removal significantly extended total and postoperative hospitalization times, antibiotic usage duration, and hospitalization cost. In addition, postoperative infection and antibiotic usage were independent factors for delayed DT removal.

Research conclusions

Postoperative infection and antibiotic usage were vital independent factors that influenced delayed DT removal in GC patients with CA. Appropriate and lenient standards for DT removal may significantly reduce the duration of hospitalization.

Research perspectives

DT clamping could be recommended as an alternative for conservative treatment of postoperative CA.

ACKNOWLEDGEMENTS

We thank Dr. Xuan Li for statistical advising and review of the manuscript.

FOOTNOTES

Author contributions: Kong PF and Xu YH contributed equally to this work; Xu DZ designed the research study; Kong PF, Xu YH, Lai ZH and Sun B performed the research; Kong PF, Xu YH, Ma MZ and Duan YT analyzed the data and wrote the manuscript; all authors have read and approve the final manuscript.

Institutional review board statement: The study was reviewed and approved by Ethics Committee of Fudan University Shanghai Cancer Center Review Board [Approval No. FUSCC-D-2021-164].

Informed consent statement: All study participants provided informed written consent prior to study enrollment.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Data sharing statement: Dataset available from the corresponding author at xudzh@shca.org.cn. Participants gave informed consent for data sharing.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Ming-Zhe Ma 0000-0001-8858-0983; Da-Zhi Xu 0000-0002-2265-1272.

S-Editor: Gong ZM

L-Editor: A

P-Editor: Yuan YY

REFERENCES

- 1 Cárdenas A, Chopra S. Chylous ascites. *Am J Gastroenterol* 2002; **97**: 1896-1900 [PMID: 12190151 DOI: 10.1111/j.1572-0241.2002.05911.x]
- 2 Huang Q, Jiang ZW, Jiang J, Li N, Li JS. Chylous ascites: treated with total parenteral nutrition and somatostatin. *World J Gastroenterol* 2004; **10**: 2588-2591 [PMID: 15300913 DOI: 10.3748/wjg.v10.i17.2588]
- 3 Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. *CA Cancer J Clin* 2020; **70**: 145-164 [PMID: 32133645 DOI: 10.3322/caac.21601]
- 4 Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K; Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal

- dissection for gastric cancer. *N Engl J Med* 2008; **359**: 453-462 [PMID: 18669424 DOI: 10.1056/NEJMoa0707035]
- 5 **Yol S**, Bostanci EB, Ozogul Y, Ulas M, Akoglu M. A rare complication of D3 dissection for gastric carcinoma: chyloperitoneum. *Gastric Cancer* 2005; **8**: 35-38 [PMID: 15747172 DOI: 10.1007/s10120-004-0312-5]
- 6 **Ilhan E**, Demir U, Alemdar A, Ureyen O, Eryavuz Y, Mihmanli M. Management of high-output chylous ascites after D2-lymphadenectomy in patients with gastric cancer: a multi-center study. *J Gastrointest Oncol* 2016; **7**: 420-425 [PMID: 27284475 DOI: 10.21037/jgo.2016.02.03]
- 7 **Lu J**, Wei ZQ, Huang CM, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Chen QY, Cao LL, Lin M. Small-volume chylous ascites after laparoscopic radical gastrectomy for gastric cancer: results from a large population-based sample. *World J Gastroenterol* 2015; **21**: 2425-2432 [PMID: 25741151 DOI: 10.3748/wjg.v21.i8.2425]
- 8 **Pabst TS 3rd**, McIntyre KE Jr, Schilling JD, Hunter GC, Bernhard VM. Management of chyloperitoneum after abdominal aortic surgery. *Am J Surg* 1993; **166**: 194-8; discussion 198 [PMID: 8352415 DOI: 10.1016/s0002-9610(05)81055-4]
- 9 **Barchi LC**, Charruf AZ, de Oliveira RJ, Jacob CE, Ceconello I, Zilberstein B. Management of postoperative complications of lymphadenectomy. *Transl Gastroenterol Hepatol* 2016; **1**: 92 [PMID: 28138657 DOI: 10.21037/tgh.2016.12.05]
- 10 **Bhardwaj R**, Vaziri H, Gautam A, Ballesteros E, Karimeddini D, Wu GY. Chylous Ascites: A Review of Pathogenesis, Diagnosis and Treatment. *J Clin Transl Hepatol* 2018; **6**: 105-113 [PMID: 29577037 DOI: 10.14218/JCTH.2017.00035]
- 11 **Aalami OO**, Allen DB, Organ CH Jr. Chylous ascites: a collective review. *Surgery* 2000; **128**: 761-778 [PMID: 11056439 DOI: 10.1067/msy.2000.109502]
- 12 **Lizaola B**, Bonder A, Trivedi HD, Tapper EB, Cardenas A. Review article: the diagnostic approach and current management of chylous ascites. *Aliment Pharmacol Ther* 2017; **46**: 816-824 [PMID: 28892178 DOI: 10.1111/apt.14284]
- 13 **Lopez-Gutierrez JC**, Tovar JA. Chylothorax and chylous ascites: management and pitfalls. *Semin Pediatr Surg* 2014; **23**: 298-302 [PMID: 25459015 DOI: 10.1053/j.sempedsurg.2014.09.011]
- 14 **Shibuya Y**, Asano K, Hayasaka A, Shima T, Akagi K, Ozawa N, Wada Y. A novel therapeutic strategy for chylous ascites after gynecological cancer surgery: a continuous low-pressure drainage system. *Arch Gynecol Obstet* 2013; **287**: 1005-1008 [PMID: 23224652 DOI: 10.1007/s00404-012-2666-y]
- 15 **Kim J**, Won JH. Percutaneous Treatment of Chylous Ascites. *Tech Vasc Interv Radiol* 2016; **19**: 291-298 [PMID: 27993325 DOI: 10.1053/j.tvir.2016.10.006]
- 16 **Kaas R**, Rustman LD, Zoetmulder FA. Chylous ascites after oncological abdominal surgery: incidence and treatment. *Eur J Surg Oncol* 2001; **27**: 187-189 [PMID: 11289756 DOI: 10.1053/ejso.2000.1088]
- 17 **Kim DW**, Kim MH, Kim CG. Lymphoscintigraphy revealed chyloperitoneum after gastrectomy for gastric cancer. *Clin Nucl Med* 2015; **40**: 41-44 [PMID: 25310405 DOI: 10.1097/RLU.0000000000000609]
- 18 **Adler E**, Bloyd C, Wlodarczyk S. Chylous Ascites. *J Gen Intern Med* 2020; **35**: 1586-1587 [PMID: 31720957 DOI: 10.1007/s11606-019-05532-3]
- 19 **Thiel FC**, Parvanta P, Hein A, Mehlhorn G, Lux MP, Renner SP, Preisner A, Beckmann MW, Schrauder MG. Chylous ascites after lymphadenectomy for gynecological malignancies. *J Surg Oncol* 2016; **114**: 613-618 [PMID: 27378217 DOI: 10.1002/jso.24354]
- 20 **Miserochi G**. Physiology and pathophysiology of pleural fluid turnover. *Eur Respir J* 1997; **10**: 219-225 [PMID: 9032518 DOI: 10.1183/09031936.97.10010219]
- 21 **Yan S**, Wang X, Wang Y, Lv C, Wang J, Yang Y, Wu N. Intermittent chest tube clamping may shorten chest tube drainage and postoperative hospital stay after lung cancer surgery: a propensity score matching analysis. *J Thorac Dis* 2017; **9**: 5061-5067 [PMID: 29312711 DOI: 10.21037/jtd.2017.11.08]
- 22 **Scaletta G**, Quagliozzi L, Cianci S, Vargiu V, Mele MC, Scambia G, Fagotti A. Management of postoperative chylous ascites after surgery for ovarian cancer: a single-institution experience. *Updates Surg* 2019; **71**: 729-734 [PMID: 31006086 DOI: 10.1007/s13304-019-00656-x]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

